GLIMPSE study: exploring the effectiveness of glimepiride and metformin combination therapy in newly diagnosed type 2 diabetes in India
DOI:
https://doi.org/10.18203/2349-3933.ijam20251937Keywords:
Glimepiride, Metformin, Glycemic control, Fixed dose combination, Type 2 diabetes mellitusAbstract
Background: Glimepiride and metformin FDC are still relevant in Indian settings as it promotes beta cell responsiveness, protects them from apoptosis and is highly cost-effective. The study aims to primarily understand the usage pattern of initial combination therapy of metformin and glimepiride in newly diagnosed T2DM patients in India.
Methods: A retrospective multi-center cross-sectional study was conducted on 17994 newly diagnosed diabetic patients receiving an FDC of glimepiride and metformin. Baseline data included patient demographics and clinical examination findings, while glycemic parameters were measured at baseline and after 3 months of combination therapy. Key variables assessed included FDC strength, dosage frequency and the rationale for selecting the glimepiride-metformin combination. The clinician’s global assessment of therapy safety and effectiveness was also recorded.
Results: The most frequently prescribed fixed-dose combinations (FDCs) were glimepiride 2 mg with metformin 500 mg (30.49%) and glimepiride 1 mg with metformin 500 mg (30.15%). Age was a significant determinant in the selection of combination therapy (p<0.001). At baseline, the mean hemoglobin A1c (HbA1c) level was 8.3%, which significantly improved to 7.3% following treatment for 3 months (p<0.001). Post-treatment FBG levels decreased from 172.8 mg/dl to 134.2 mg/dl, while postprandial blood glucose (PPBG) levels were reduced from 245.9 mg/dl to 187.8 mg/dl (both p<0.001). The majority of patients demonstrated either excellent or good outcomes based on the clinician’s global assessment of treatment effectiveness and safety.
Conclusions: Metformin 500 mg with either 1 mg or 2 mg of glimepiride is the most frequently prescribed FDC in newly diagnosed T2DM patients as it offers mechanistic complementarity for insulin resistance and β-cell dysfunction, with good safety profile, along with cost effectiveness.
Metrics
References
World Health Organization (WHO). Diabetes in India. Available at: https://www.who.int. Accessed on 21 November 2024.
Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L. IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s Criteria. Diabetes Res. 2022;183:109050. DOI: https://doi.org/10.1016/j.diabres.2021.109050
Pandey SK, Sharma V. World diabetes day 2018: Battling the Emerging Epidemic of Diabetic Retinopathy. Indian J Ophthalmol. 2018;66(11):1652–3. DOI: https://doi.org/10.4103/ijo.IJO_1681_18
Rajalakshmi R, Vasconcelos JC, Prevost AT, Sivaprasad S, Deepa M, Raman R, et al. Burden of undiagnosed and suboptimally controlled diabetes in selected regions of India: Results from the SMART India population‐level diabetes screening study. Diabet Med. 2023;40(10):15165. DOI: https://doi.org/10.1111/dme.15165
Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum. Indian J Endocrinol Metab. 2016;20(4):546–51. DOI: https://doi.org/10.4103/2230-8210.183480
Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463–72. DOI: https://doi.org/10.2147/VHRM.S33194
Kumar S. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients. Indian J Endocrinol Metab. 2021;25(4):326–31. DOI: https://doi.org/10.4103/ijem.ijem_276_21
Singh S. Commentary on “Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force.” Indian J Endocrinol Metab. 2018;22(1):158. DOI: https://doi.org/10.4103/ijem.IJEM_22_18
Ag U, Mv A. Clinical Utilization Pattern of Multiple Strengths of Glimepiride and Metformin Fixed Dose Combinations in Indian Type 2 Diabetes Patients. J Assoc Physicians India. 2020;68(7):57–61.
Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S, et al. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Indian J Endocrinol Metab. 2020;24(1):1–122. DOI: https://doi.org/10.4103/ijem.IJEM_225_20
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(1):111–24. DOI: https://doi.org/10.2337/dc21-S009
Sinha B, Kant S, Bandyopadhyay S, Mukherjee S, Sarkar D, Singh KP, et al. Clinical Utility of Glimepiride and Metformin Fixed-Dose Combination in Obese/Overweight Patients with Type 2 Diabetes Mellitus in Indian Settings. Chron Diabetes Res Pract. 2022;1(2):58–68. DOI: https://doi.org/10.4103/cdrp.cdrp_5_22
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;24;322(12):1155–66. DOI: https://doi.org/10.1001/jama.2019.13772
Kalra S, Das AK, Baruah MP, Unnikrishnan AG, Dasgupta A, Shah P, et al. Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group. Diabetes Ther. 2019;10(5):1577–93. DOI: https://doi.org/10.1007/s13300-019-0651-1
Sheikh S, Nagendra L, Sinha B, Bansal B, Dey A, Kumar S, et al. Usage of Glimepiride and Metformin Combination in Type 2 Diabetes Patients with Established Complications in Indian Settings. Int J Diabetes Technol. 2024;3(2):74–9. DOI: https://doi.org/10.4103/ijdt.ijdt_23_24
Rojas J, Añez R, Martínez MS, Chacín M, Salazar J, Calvo MJ, et al. New horizons in glimepiride and metformin Mechanisms of action. 2016;
Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014;5(6):701–8. DOI: https://doi.org/10.1111/jdi.12201
Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G. Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence. Cureus. 2020;12(9):68. DOI: https://doi.org/10.7759/cureus.10700
Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion. Diabetes Metab. 2005;31:527-34. DOI: https://doi.org/10.1016/S1262-3636(05)73649-1
Lee SH. The Growing Challenge of Diabetes Management in an Aging Society. Diabetes Metab J. 2023;30;47(5):630–1. DOI: https://doi.org/10.4093/dmj.2023.0279
Díez-Villanueva P, Jiménez-Méndez C, Bonanad C, García-Blas S, Pérez-Rivera Á, Allo G, et al. Risk Factors and Cardiovascular Disease in the Elderly. Rev Cardiovasc Med. 2022;23(6):188. DOI: https://doi.org/10.31083/j.rcm2306188
Yu HM, Kim SJ, Chun SW, Park KY, Lim DM, Lee JM, et al. A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. Diabetes Res Clin Pract. 2019;155:107796. DOI: https://doi.org/10.1016/j.diabres.2019.107796
Tandon T, Dubey A, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. J Fam Med Prim Care. 2019;8(3):955. DOI: https://doi.org/10.4103/jfmpc.jfmpc_22_19
Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better. Diabetes Care. 2014;1;37(5):1338–45. DOI: https://doi.org/10.2337/dc13-1901
Gu S, Tang Z, Shi L, Sawhney M, Hu H, Dong H. Cost-minimization analysis of metformin and acarbose in treatment of type 2 diabetes. Value Health Reg Issues. 2015;6:84–8. DOI: https://doi.org/10.1016/j.vhri.2015.03.012
Downloads
Published
How to Cite
Issue
Section
